92 studies found for:    MPL
Show Display Options
Rank Status Study
1 Active, not recruiting LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
Condition: Leishmaniasis
Interventions: Drug: GLA-SE;   Drug: MPL-SE;   Drug: SE;   Biological: LEISH-F3
2 Completed Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Condition: Type I Hypersensitivity
Intervention: Biological: Tree MATA MPL
3 Completed Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Condition: Type I Hypersensitivity
Intervention: Biological: OralvacB2MPL
4 Completed Efficacy and Safety/Tolerability of Grass MATA MPL
Condition: Type I Hypersensitivity
Interventions: Biological: Grass MATA MPL;   Biological: Placebo
5 Completed Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Condition: Type I Hypersensitivity
Intervention: Biological: Tree MATA MPL
6 Completed
Has Results
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Biological: LEISH-F2 + MPL-SE;   Drug: Sodium stibogluconate
7 Completed Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine Formulation A;   Biological: HBV-MPL vaccine Formulation B;   Biological: Engerix™-B
8 Completed Efficacy and Safety/Tolerability of Ragweed MATA MPL
Condition: Type I Hypersensitivity
Intervention: Biological: Ragweed MATA MPL
9 Completed Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
Condition: Type I Hypersensitivity
Intervention: Biological: Ragweed MATA MPL
10 Completed Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
11 Completed Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
12 Completed Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules
Condition: Hepatitis B
Interventions: Biological: Engerix™-B;   Biological: HBV-MPL vaccine
13 Completed Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL
Condition: Post Kala Azar Dermal Leishmaniasis
Intervention: Biological: LEISH-F2 + MPL-SE vaccine
14 Completed Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine;   Biological: Engerix™-B
15 Not yet recruiting Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children
Condition: Norovirus
Interventions: Biological: GI.1/GII.4 (15/15) - MPL (50);   Biological: GI.1/GII.4 (15/50) - MPL (50);   Biological: GI.1/GII.4 (50/50) - MPL (50);   Biological: GI.1/GII.4 (15/15) - MPL (15);   Biological: GI.1/GII.4 (15/50) - MPL (15);   Biological: GI.1/GII.4 (50/50) - MPL (15);   Biological: GI.1/GII.4 (15/15);   Biological: GI.1/GII.4 (15/50);   Biological: GI.1/GII.4 (50/50);   Biological: GI.1/GII.4 (50/150);   Biological: GI.1/GII.4 (15/50) - Al(OH)3 (167);   Drug: Placebo
16 Completed Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine 208129;   Biological: Engerix™-B
17 Completed Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients
Condition: Hepatitis B
Interventions: Biological: HBV-MPL vaccine 208129;   Biological: Engerix™-B
18 Completed Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
Condition: Leishmaniasis, Cutaneous
Intervention: Biological: Leish-111f + MPL-SE vaccine
19 Completed Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
Condition: Cutaneous Leishmaniasis
Intervention: Biological: Leish-111f + MPL-SE vaccine
20 Completed Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
Condition: Leishmaniasis, Mucocutaneous
Intervention: Biological: Leish-111f + MPL-SE vaccine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years